Posttreatment assessment of women at risk of developing high-grade cervical disease: Proposal for New Guidelines Based on Data From The Netherlands

Journal of Lower Genital Tract Disease

Volumn 18, Issue 4, 2014, Pages 338-343

  Uijterwaal, Margot H ^a   Kocken, Mariëlle ^a   Berkhof, Johannes ^a   Bekkers, Ruud L M ^b   Verheijen, Réne H M ^c   Helmerhorst, Theo J M ^d   Meijer, Chris J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cervix; CIN2 3; Cytology; HrHPV; Posttreatment

Indexed keywords

ARTICLE; CANCER CYTODIAGNOSIS; CANCER GRADING; CANCER RISK; CANCER THERAPY; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; DISEASE SURVEILLANCE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; NETHERLANDS; PERSISTENT INFECTION; PRACTICE GUIDELINE; SENSITIVITY AND SENSIBILITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLASSIFICATION; COMPLICATION; CYTOLOGY; EARLY DIAGNOSIS; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; UTILIZATION;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTOLOGICAL TECHNIQUES; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MICROBIOLOGICAL TECHNIQUES; NETHERLANDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 84915760657     PISSN: 10892591     EISSN: 15260976     Source Type: Journal    
DOI: 10.1097/lgt.0000000000000012     Document Type: Article

References (42)

1. Prismant. Ziekenhuisstatistieken; ingrepen cervix [Hospitadata; procedures on the cervix [Internet]; 2008. Available from: http:///prismant.nl/informatieproducten/ziekenhuisstatistieken [in Dutch]. Accessed April 2010
2. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses. Vaccine 2006;24(suppl 3):S3/78Y89
3. Kocken M, Helmerhorst TJ, Berkhof J, Louwers JA, Nobbenhuis MA, Bais AG, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: A long-term multi-cohort study. Lancet Oncol 2011;12:441Y50
4. Bleeker MC, Meijer CJ, Berkhof J. Follow-up after treatment for cervical intraepithelial neoplasia. BMJ 2012;345:e7186
5. Werkgroep Oncologische Gynaecologie. NVOG richtlijn Cervicale Intra-epitheliale Neoplasia [National Guideline Cervical Intraepithelial Neoplasia] [Internet]; 2008. Available from: http://nvog-documenten. nl/index.php?pagina = /richtlijn/pagina.php&fSelectTG-62=75&fSelectedSub=62&fSelectedParent=75[in Dutch]. Accessed March 12, 2013
6. NHS. Colposcopy and programme management: guidelines for the NHS Cervical Screening Programme (Second Edition) [Internet]; 2010. Available from: http://www.cancerscreening.nhs.uk/cervical/ publications/nhscsp20.pdf. Accessed March 12, 2013
7. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis 2007;11:223-39
8. Bais AG, Eijkemans MJ, Rebolj M, Snijders PJ, Verheijen RH, van BM, et al. Post-treatment CIN: randomised clinical trial using hrHPV testing for prediction of residual/recurrent disease. Int J Cancer 2009;124:889Y95
9. Zielinski GD, Rozendaal L, Voorhorst FJ, Berkhof J, Snijders PJ, Risse EJ, et al. HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3. Gynecol Oncol 2003;91:67Y73
10. Rebolj M, Helmerhorst TJ, Habbema D, Looman C, Boer R, van Rosmalen J, et al. Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: Population-based cohort study. BMJ 2012;345:e6855
11. Kocken M, Uijterwaal MH, de Vries AL, Berkhof J, Ket JC, Helmerhorst TJ, et al. High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: A systematic review and meta-analysis. Gynecol Oncol 2012;125:500Y7
12. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012;30(suppl 5):F88Y99
13. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second editionVsummary document. Ann Oncol 2010;21:448Y58
14. HPV Triage and Test of Cure Protocol [Internet]; 2011. Available from: http://www.cancerscreening.nhs.uk/cervical/hpv-triage-test-ofcure- flowchart.pdf. Accessed October 16, 2012
15. Sundhedsstyrelsen. Screening for livmoderhalskr&ft [cervical cancer screening] [Internet]. Copenhagen, Denmark [Table]; Guidelines for follow-up after conisation [about 1 screen]. Available from: http://www.sst.dk/publ/Publ2012/SYB/Kraeft/ScreenLivmoderhalskrftAnbef.pdf [in Danish]. Accessed October 16, 2012.
16. Health Council of the Netherlands. Population screening for cervical cancer [Internet]. The Hague, the Netherlands; 2011. Available from: http://www.gezondheidsraad.nl/sites/default/files/201107E-PopulationSCC-0.pdf [in Dutch]. Accessed October 16, 2012.
17. Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004;110:94Y101
18. Nobbenhuis MA, Meijer CJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Risse EK, et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 2001;84:796Y801
19. Chan BK, Melnikow J, Slee CA, Arellanes R, Sawaya GF. Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: A systematic review. Am J Obstet Gynecol 2009;200:422Y9
20. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095Y101
21. Heymans J, Benoy IH, Poppe W, Depuydt CE. Type-specific HPV geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation. Int J Cancer 2011;129:903Y9
22. Kitchener HC,Walker PG, Nelson L, Hadwin R, Patnick J, Anthony GB, et al. HPV testing as an adjunct to cytology in the follow up of women treated for cervical intraepithelial neoplasia. BJOG 2008;115:1001Y7
23. Paraskevaidis E, Arbyn M, Sotiriadis A, Diakomanolis E, Martin-Hirsch P, Koliopoulos G, et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: A systematic review of the literature. Cancer Treat Rev 2004;30:205Y11
24. Strander B, Ryd W, Wallin KL, Warleby B, Zheng B, Milsom I, et al. Does HPV-status 6Y12 months after treatment of high grade dysplasia in the uterine cervix predict long term recurrence? Eur J Cancer 2007;43:1849Y55
25. Zielinski GD, Bais AG, Helmerhorst TJ, Verheijen RH, de Schipper FA, Snijders PJ, et al. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv 2004;59:543Y53
26. Persad VL, Pierotic MA, Guijon FB. Management of cervical neoplasia: A 13-year experience with cryotherapy and laser. J Low Genit Tract Dis 2001;5:199Y203
27. Melnikow J, McGahan C, Sawaya GF, Ehlen T, Coldman A. Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. J Natl Cancer Inst 2009;101:721Y8
28. Kalliala I, Anttila A, Pukkala E, Nieminen P. Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study. BMJ 2005;331:1183Y5
29. Soutter WP, de Barros LA, Fletcher A, Monaghan JM, Duncan ID, Paraskevaidis E, et al. Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet 1997;349:978Y80
30. Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer 2006;118:2048Y55
31. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: Performance of HPVand Pap cotesting in posttreatment management. J Low Genit Tract Dis 2013;17(5 suppl 1):S78Y84
32. Elfgren K, Jacobs M, Walboomers JM, Meijer CJ, Dillner J. Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. Obstet Gynecol 2002;100(5 Pt 1):965Y71
33. Kreimer AR, Guido RS, Solomon D, Schiffman M, Wacholder S, Jeronimo J, et al. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev 2006;15:908Y14
34. Prato B, Ghelardi A, Gadducci A, Marchetti I, Di CC, Di CG, et al. Correlation of recurrence rates and times with posttreatment human papillomavirus status in patients treated with loop electrosurgical excision procedure conization for cervical squamous intraepithelial lesions. Int J Gynecol Cancer 2008;18:90Y4
35. Alonso I, Torne A, Puig-Tintore LM, Esteve R, Quinto L, Campo E, et al. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. Gynecol Oncol 2006;103:631-6
36. Louwers J, Zaal A, Kocken M, Ter Harmsel WA, Graziosi G, Spruijt J, et al. Dynamic spectral imaging colposcopy: higher sensitivity for detection of premalignant cervical lesions. BJOG 2011;118:309Y18
37. Gage JC, Hanson VW, Abbey K, Dippery S, Gardner S, Kubota J, et al. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 2006;108:264Y72
38. Nam K, Chung S, Kwak J, Cha S, Kim J, Jeon S, et al. Random biopsy after colposcopy-directed biopsy improves the diagnosis of cervical intraepithelial neoplasia grade 2 or worse. J Low Genit Tract Dis 2010;14:346Y51
39. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013 Apr;121(4):829Y46
40. Gross PA, Barrett TL, Dellinger EP, Krause PJ, Martone WJ, McGowan JE Jr, et al. Quality standard for the treatment of bacteremia. Infectious Diseases Society of America. Clin Infect Dis 1994;18:428-30
41. Coupe VM, Berkhof J, Verheijen RH, Meijer CJ. Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. BJOG 2007;114:416-24
42. Costa S, Venturoli S, Negri G, Sideri M, Preti M, Pesaresi M, et al. Factors predicting the outcome of conservatively treated adenocarcinoma in situ of the uterine cervix: An analysis of 166 cases. Gynecol Oncol 2012;124:490Y5.